<DOC>
	<DOCNO>NCT01423916</DOCNO>
	<brief_summary>The purpose study establish pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , adverse event ( AE ) profile OPC-34712 administer schizophrenic/schizoaffective subject . The goal trial three-fold : - To determine effect OPC-34712 individual QT interval ( QTcI ) correct placebo - To determine effect moxifloxacin QTcI - To examine concentration-effect relationship OPC-34712 moxifloxacin QTcI</brief_summary>
	<brief_title>Trial Evaluate Effects OPC-34712 QT/QTc Subjects With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive , diagnosis schizophrenia schizoaffective disorder define DSMIVTR criterion . Body mass index 19 35 kg/m2 . Females pregnant lactating . A negative serum pregnancy test must confirm prior first dose trial medication female subject . Subjects present first episode schizophrenia schizoaffective disorder base clinical judgment investigator . Subjects receive continuous medication therapy treat schizophrenia schizoaffective disorder le 6 month prior washout . Subjects schizophrenia schizoaffective disorder consider resistant/refractory antipsychotic treatment history , history failure clozapine , responsive clozapine treatment . Subjects current DSMIVTR Axis I diagnosis schizophrenia schizoaffective disorder . Hospitalization exacerbation schizophrenia schizoaffective disorder within 3 month prior randomization . Subjects history evidence medical and/or neurological condition would expose undue risk significant AE interfere assessment safety efficacy course trial . Subjects history neuroleptic malignant syndrome . Subjects history seizure disorder . Subjects meet DSMIVTR criterion substance dependence within 6 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>QTc Interval</keyword>
</DOC>